No Data
No Data
Sector Update: Health Care
Health care stocks rose late Friday afternoon with the NYSE Health Care Index advancing 0.9% and the Health Care Select Sector SPDR Fund (XLV) up 0.8%. The iShares Biotechnology ETF (IBB) eased 0.1%.
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise
KalVista Pharmaceuticals (KALV) was advancing 4% Friday after the drugmaker said a late-stage trial of its candidate, sebetralstat, to treat hereditary angioedema, a swelling disorder, met primary and
Express News | KalVista Pharmaceuticals Presents Late-Breaking Phase 3 KONFIDENT Trial Data On Sebetralstat At EAACI Congress; NEJM Publication Highlights 9-Minute Median Time To Treatment And 1.3-Hour Symptom Relief For Laryngeal Attacks In KONFIDENT-S Trial
Express News | Kalvista Pharmaceuticals : Look Forward to Submitting New Drug Application for Sebetralstat to FDA in June 2024 & in EU and Japan Later This Year
Stifel Nicolaus Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People With Hereditary Angioedema
– Late-breaking data from phase 3 KONFIDENT trial of sebetralstat published in NEJM and presented concurrently at the European Academy of Allergy and Clinical Immunology Congress 2024 –– Interim data
No Data